Tokyo, Japan and Cambridge, UK, 23 June 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study. HTL0022562 (also known as BHV3100) is a novel, small molecule CGRP* receptor antagonist discovered by Sosei Heptares and the lead compound in a portfolio of CGRP antagonists licensed to Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN) in December 2020 for development as new therapies for CGRP-mediated disorders.
The trial is a Phase 1, randomized, double-blind, placebo-…
AMSBIO invite the global research community to the 2021 annual meeting of the ISSCR, the leading professional organization of stem cell scientists, to discover how iPSCs and organoids can be used in COVID-19 drug discovery research.At this virtual meeting - Dr. Kazuo Takayama from the renowned Center for iPS Cell Research and application (CiRA) at Kyoto University will be giving a unique insight into his recent pioneering research that has successfully modelled the SARS-CoV-2 life cycle in undifferentiated iPSCs, which were previously uninfectable. This innovation showcase…
CAMBRIDGE, England--(BUSINESS WIRE)--Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing potentially transformative treatments based on breakthrough discoveries, has completed a $145 million (over £100 million) financing. The financing was led by Patient Square Capital, which will take a controlling position in the business, with participation from additional investors including Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. Proceeds from the investment will support advancement of Apollo’s robust pipeline into development, expansion of the…
Leading pharmaceutical and biotech product development consultancy Boyds has added to its regulatory team with the appointments of Shalini Gupta and Sarah Stevenson in response to recent growth and the continued increase in demand for its dedicated regulatory services.
Shalini Gupta joins the company as Senior Manager, Regulatory Affairs, and brings over 10 years of industry experience in regulatory submissions across a wide range of biologics and pharmaceutical products including advanced cell and gene therapy products. Shalini has specific expertise in CMC and regulatory aspects of EU…
NOTTINGHAM, UK – 16 June, 2021 – Life Science Newswire – Leading Drug Discovery Contract Research Organisation Sygnature Discovery has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials.With over £1m of capital investment already committed, the new world-class facility and business unit will be operational in September 2021 and is being set…
Health, Safety and Biosafety Consultant, Dr Bishop Simon, will be presenting a free biosafety webinar in collaboration with the Institution of Occupational Safety and Health. This session offers insight into the controls used by safety professionals to protect our laboratory research scientist and the community around them, as they work to make the discoveries needed to advance the treatment of diseases. This session will be of interest to you if: a) you are curious about how this is achieved in general and during the COVID pandemic, b) if you've considered working in the sector as a…
Cambridge, UK, 14 June 2021: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has appointed Dr Christian Dillon as Vice President of Biology. In this new role, Dr Dillon will work across all the Company’s areas of interest, including oncology, targeted protein degradation, and neurodegeneration, leading PhoreMost’s efforts to progress the novel targets identified by its SITESEEKER® platform towards drug discovery.
Christian joins PhoreMost from Cancer Research UK’s Therapeutic Discovery Laboratories (CRUK-TDL…
The next round of the Biomedical Catalyst will launch on 7th June. £18 Million is available to support industry-led research and development projects that seek to provide solutions to Health and Care challenges.
The Biomedical Catalyst funding programme supports UK businesses to test and develop innovative technologies for health and care. The programme provides funding to help UK SMEs speed up the process of bringing new products to market and secure onward investment.
The Biomedical Catalyst was established in 2012 with the aim of delivering…
Air Products is pleased to announce that it has extended its agreement with One Nucleus for another two years. It means that One Nucleus members can benefit from preferential rates on liquid gases and associated equipment from Air Products until at least 2023.
As a preferred partner of One Nucleus, members have access to Air Products’ full range of liquid gases and associated equipment, including freezers, tanks and cryogenic shippers. Stephen Robinson, Life Science Product Manager at Air Products, commented that: “Through our partnership with One Nucleus we have the opportunity to work with…
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER
Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief Operating Officer.
Lindsey brings a wealth of deep expertise and experience from the life science industry, with roles covering strategy, marketing, project management and corporate development. Having completed a PhD in…